

( (S (NP-SBJ (NP Gen-Probe Inc.)
             ,
             (NP a biotechnology concern)
             ,)
     (VP said
         (SBAR 0
               (S (NP-SBJ it)
                  (VP signed
                      (NP a definitive agreement
                          (S (NP-SBJ-1 *)
                             (VP to
                                 (VP be
                                     (VP acquired
                                         (NP *-1)
                                         (PP by
                                             (NP-LGS (NP Chugai Pharmaceutical Co.)
						     (PP of
							 (NP Tokyo))))
                                         (PP-CLR for
						 (NP (NP (QP about $ 110 million) *U*)
						     , or
						     (NP (NP (QP almost double)
							     the market price)
							 (PP of
							     (NP (NP Gen-Probe 's)
								 stock))))))))))))))
     .))
( (S (NP-SBJ-1 The move)
     (VP is
         (ADJP-PRD sure
		   (S (NP-SBJ *-1)
		      (VP to
			  (VP heighten
			      (NP (NP concerns)
				  (PP about
				      (NP (NP increased Japanese investment)
					  (PP-LOC in
						  (NP U.S. biotechnology firms))))))))))
     .))
( (S (NP-SBJ-1 It)
     (VP is
         (ADVP also)
         (ADJP-PRD likely
		   (S (NP-SBJ *-1)
		      (VP to
			  (VP bolster
			      (NP fears
				  (SBAR that
					(S (NP-SBJ-2 the Japanese)
					   (VP will
					       (VP use
						   (NP (NP their foothold)
						       (PP-LOC in
							       (NP U.S. biotechnology concerns)))
						   (S-CLR (NP-SBJ *-2)
							  (VP to
							      (VP gain
								  (NP certain (UCP trade and competitive) advantages))))))))))))))
     .))
( (S (NP-SBJ (NP Gen-Probe)
             ,
             (NP (NP an industry leader)
                 (PP-LOC in
			 (NP (NP the field)
			     (PP of
				 (NP (NP genetic probes)
				     ,
				     (SBAR (WHNP-2 which)
					   (S (NP-SBJ *T*-2)
					      (VP is
						  (NP-PRD (NP a new technology)
							  (VP used
							      (NP *)
							      (PP-LOC in
								      (NP diagnostic tests))))))))))))
             ,)
     (NP-TMP last year)
     (VP signed
         (NP an agreement
             (SBAR for
                   (S (NP-SBJ Chugai)
                      (VP to
                          (VP (ADVP exclusively)
                              market
                              (NP (NP its diagnostic products)
                                  (PP *ICH*-1))
                              (PP-LOC in
				      (NP Japan))
                              (PP-1 for
                                    (NP (NP infectious diseases)
                                        and
                                        (NP cancer)))))))))
     .))
( (S (NP-SBJ-1 Chugai)
     (VP agreed
         (ADVP-TMP then)
         (S (NP-SBJ *-1)
            (VP to
                (VP fund
                    (NP certain associated research and development costs)))))
     .))
( (S (S (NP-SBJ That arrangement)
        (ADVP apparently)
        (VP has
            (VP worked
                (ADVP-MNR well))))
     , and
     (S (NP-SBJ (NP Thomas A. Bologna)
                ,
                (NP (NP (NP president) and (NP chief executive officer))
                    (PP of
                        (NP (NP Gen-Probe)
                            ,
                            (VP founded
                                (NP *)
                                (PP-TMP in
					(NP 1983))))))
                ,)
        (VP said
            (SBAR 0
                  (S (NP-SBJ (NP the sale)
                             (PP of
                                 (NP the company)))
                     (VP means
                         (SBAR 0
			       ``
			       (S (NP-SBJ-1 we)
                                  (VP will
                                      (VP be
                                          (ADJP-PRD able
						    (S (NP-SBJ *-1)
						       (VP to
							   (VP concentrate
							       (PP-CLR on
								       (S-NOM (NP-SBJ *)
									      (VP (VP running
										      (NP the business))
										  (CONJP rather than)
										  (VP (ADVP-TMP always)
										      looking
										      (PP-CLR for
											      (NP (NP sources)
												  (PP of
												      (NP financing)))))))))))))))))))))
     .
     ''))
( (S (NP-SBJ-1 Chugai)
     (VP agreed
         (S (NP-SBJ *-1)
            (VP to
                (VP pay
                    (NP (NP $ 6.25 *U*)
                        (NP-ADV a share))
                    (PP-CLR for
			    (NP (NP (NP Gen-Probe 's)
				    (QP 17.6 million)
				    common shares)
				(ADJP outstanding)))
                    (PP on
                        (NP a
                            (ADJP fully diluted)
                            basis))))))
     .))
( (S (NP-TMP Yesterday)
     ,
     (PP-LOC in
	     (NP (NP national trading)
		 (PP-LOC in
			 (NP the over-the-counter market))))
     ,
     (NP-SBJ Gen-Probe common)
     (VP closed
         (PP-CLR at
		 (NP (NP $ 3.25 *U*)
		     (NP-ADV a share))))
     .))
( (S (SBAR-PRP Because
	       (S (NP-SBJ the U.S.)
		  (VP leads
		      (PP-CLR in
			      (NP (NP most areas)
				  (PP of
				      (NP biotechnology))))
		      --
		      (PP-PRP (ADVP largely) 
			      because of
			      (NP (NP research investment)
				  (PP by
				      (NP-LGS the U.S. government))))
		      --)))
     (NP-SBJ-1 the sale)
     (VP is
         (ADJP-PRD sure
		   (S (NP-SBJ *-1)
		      (VP to
			  (VP increase
			      (NP concerns
				  (SBAR that
					(S (NP-SBJ-2 Japanese companies)
					   (VP will
					       (VP (VP buy
						       (NP American know-how))
						   and
						   (VP use
						       (NP it)
						       (S-CLR (NP-SBJ *-2)
							      (VP to
								  (VP obtain
								      (NP the upper hand)
								      (PP-LOC in
									      (NP biotechnology trade and competition))))))))))))))))
     .))
((SINV ``
       (S-TPC-1 (NP-SBJ The biotechnology firms)
		(VP may
		    (VP be
			(VP setting
			    (PRT up)
			    (NP their own competitors)))))
       ,
       ''
       (VP said
	   (S *T*-1))
       (NP-SBJ (NP Richard Godown)
	       ,
	       (NP (NP president)
		   (PP of
		       (NP the Industrial Biotechnology Association))))
       .))
( (S (NP-SBJ He)
     (VP added
         (SBAR that
               (S (PP-TMP until
			  (ADVP now)) 
                  (NP-SBJ the Japanese)
                  (VP have
                      (VP (ADVP only)
                          acquired
                          (NP (NP equity positions)
                              (PP-LOC in
				      (NP U.S. biotechnology companies))))))))
     .))
( (S ``
     (S-TPC-1 (NP-SBJ They)
	      (VP are
		  (VP piggybacking
		      (PP-CLR onto
			      (NP developed technology)))))
     ,
     ''
     (NP-SBJ he)
     (VP said
	 (S *T*-1))
     .))
( (S (PP-TMP During
	     (NP the
		 past five
		 years))
     ,
     (NP-SBJ Japanese concerns)
     (VP have
         (VP invested
             (PP-CLR in
		     (NP (NP several)
			 (PP of
			     (NP (NP the U.S. 's)
				 431 independent biotechnology companies))))))
     .))
( (S (S (NP-SBJ Chugai)
        (VP has
            (VP been
                (NP-PRD (NP one)
			(PP of
			    (NP (NP the
				    (ADJP most active)
				    Japanese players)
				(PP-LOC in
					(NP U.S. biotechnology companies))))))))
     ;
     (S (NP-SBJ it)
        (VP has
            (NP (NP (NP an equity investment)
                    (PP-LOC in
			    (NP (NP Genetics Institute Inc.)
				,
				(NP-LOC (NP Cambridge)
					,
					(NP Mass.)
					,))))
                and
                (NP (NP a joint-venture agreement)
                    (PP with
                        (NP (NP Upjohn Co.)
                            ,
                            (NP-LOC (NP Kalamazoo)
				    ,
				    (NP Mich))))))))
     .))
( (S-1 (NP-SBJ The Japanese government)
       (PRN ,
	    (S (NP-SBJ Mr. Godown)
	       (VP said
		    (SBAR 0
			  (S *T*-1))))
	    ,)
       (VP has
	   (VP stated
	       (SBAR that
		     (S (NP-SBJ it)
			(VP wants
			    (S (NP-SBJ (NP (QP 10 % to 11 %) *U*)
					   (PP of
					       (NP its gross national product)))
			       (VP to
				   (VP come
				       (PP-CLR from
					       (NP biotechnology products))))))))))
       .))
( (S ``
     (S-1 (NP-SBJ It)
	  (VP is
	      (VP becoming
		  (NP-PRD (NP more)
			  (PP of
			      (NP (NP a horse race)
				  (PP *ICH*-2))))
		  (NP-TMP every day)
		  (PP-2 between
			(NP (NP the U.S.)
			    and
			    (NP Japan))))))
     ,
     ''
     (NP-SBJ-3 he)
     (VP said
	 (S *T*-1)
	 ,
	 (S-ADV (NP-SBJ *-3)
		(VP adding
		    (SBAR that
			  (S (NP-SBJ some)
			     (VP fear
				 (SBAR that
				       (S (PP as
					      (PP with
						  (NP the semiconductor , electronics , and automobile industries)))
					  ,
					  (NP-SBJ-4 Japanese companies)
					  (VP will
					      (VP use
						  (NP U.S.-developed technology)
						  (S-CLR (NP-SBJ *-4)
							 (VP to
							     (VP gain
								 (NP trade advantages))))))))))))))
     .))
( (S (NP-SBJ Mr. Bologna)
     (VP said
         (SBAR 0
               (S (NP-SBJ the sale)
                  (VP would
                      (VP allow
			  (S (NP-SBJ-1 Gen-Probe)
			     (VP (VP to
				     (VP speed
					 (PRT up)
					 (NP (NP the development)
					     (PP of
						 (NP new technology)))))
				 ,
				 and
				 (VP to
				     (ADVP-MNR more quickly)
				     (VP apply
					 (NP existing technology)
					 (PP-CLR to
						 (NP (NP an array)
						     (PP of
							 (NP (NP diagnostic products)
							     (SBAR (WHNP-2 0)
								   (S (NP-SBJ-3 the company)
								      (VP wants
									  (S (NP-SBJ *-3)
									     (VP to
										 (VP offer
										     (NP *T*-2))))))))))))))))))))
     .))
( (S (PP-TMP By
	     (NP (NP 1988)
		 ,
		 (SBAR (WHADVP-3 when)
		       (S (NP-SBJ-2 (NP (QP only 10)
					genetic probe-based tests)
				    (PP of
					(NP (NP diagnostic infectious diseases)
					    (PP of
						(NP humans)))))
			  (VP had
			      (VP been
				  (VP approved
				      (NP *-2)
				      (PP-PRP for
					      (NP marketing))
				      (PP by
					  (NP-LGS the Food and Drug Administration))
				      (ADVP-TMP *T*-3))))))))
     ,
     (NP-SBJ-4 (NP eight)
	       (PP of
		   (NP them)))
     (VP had
         (VP been
             (VP developed and sold
		 (NP *-4)
                 (PP by
		     (NP-LGS Gen-Probe)))))
     .))
( (S (NP-SBJ-3 (NP Osamu Nagayama)
	       ,
	       (NP (NP deputy president)
		   (PP of
		       (NP (NP Chugai)
			   ,
			   (SBAR (WHNP-1 which)
				 (S (NP-SBJ *T*-1)
				    (VP spends
					(NP (NP (QP about 15) %)
					    (PP of
						(NP its sales)))
					(PP-CLR on
						(NP research and development))))))))
	       ,)
     (VP was
         (ADJP-PRD unable
		   (S (NP-SBJ *-3)
		      (VP to
			  (VP pinpoint
			      (SBAR (WHNP-2 (WHADJP how much)
					    money)
				    (S (NP-SBJ Chugai)
				       (VP would
					   (VP pump
					       (NP *T*-2)
					       (PP-CLR into
						       (NP Gen-Probe)))))))))))
     .))
( (S ``
     (S-TPC-1 (NP-SBJ We)
	      (VP think
		  (SBAR 0
			(S (NP-SBJ Gen-Probe)
			   (VP has
			       (NP (NP technology)
				   (ADJP important
					 (PP to
					     (NP (NP people 's)
						 health)))))))))
     , ''
     (NP-SBJ-3 he)
     (VP said
	 (S *T*-1)
	 ,
	 (S-ADV (NP-SBJ *-3)
		(VP adding : ``
		    (S (NP-SBJ We)
		       (VP think
			   (SBAR 0
				 (S (NP-SBJ (NP it)
					    (SBAR *EXP*-4))
				    (VP is
					(ADJP-PRD important)
					(SBAR-4 for
						(S (NP-SBJ us)
						   (VP to
						       (VP have
							   (NP such technology)))))))))))))
     .
     ''))
( (S (NP-SBJ (NP He)
             and
             (NP Mr. Bologna))
     (VP emphasized
         (SBAR that
               (S (NP-SBJ both companies)
                  (VP would
                      (VP gain
                          (NP technological knowledge)
			  (PP-MNR through
				  (NP (NP the sale)
				      (PP of
					  (NP (NP Gen-Probe)
					      ,
					      (SBAR (WHNP-1 which)
						    (S (NP-SBJ *T*-1)
						       (VP will
							   (VP expand ``
							       (ADVP significantly)
							       ''
							       (PP as
								   (NP (NP a result)
								       (PP of
									   (NP the acquisition)))))))))))))))))
     .))
( (S (PP-TMP In
	     (NP 1988))
     ,
     (NP-SBJ Chugai)
     (VP had
         (NP (NP net income)
             (PP of
                 (NP (QP $ 60 million) *U*)))
	 (PP on
	     (NP (NP revenue)
		 (PP of
		     (NP (QP $ 991 million) *U*)))))
     .))
( (S (NP-SBJ GenProbe)
     (VP had
         (NP (NP a net loss)
             (PP of
                 (NP (QP $ 9.5 million) *U*)))
	 (PP on
	     (NP (NP revenue)
		 (PP of
		     (NP $ 5.8 million *U*)))))
     .))
( (S (ADVP-TMP Recently)
     ,
     (NP-SBJ Gen-Probe)
     (VP received
         (NP (NP a broad U.S. patent)
             (PP for
                 (NP (NP a technology)
                     (SBAR (WHNP-2 that)
                           (S (NP-SBJ *T*-2)
                              (VP helps
                                  (VP detect
                                      ,
                                      identify
                                      and
                                      quantify
                                      (NP non-viral organisms)
				      (PP-MNR through
					      (NP (NP the targeting)
						  (PP of
						      (NP (NP a form)
							  (PP of
							      (NP (NP genetic material)
								  (VP called
								      (S (NP-SBJ *)
									 (NP-PRD ribosomal RNA)))))))))))))))))
     .))
( (S (PP Among
         (NP other things))
     ,
     (NP-SBJ Mr. Bologna)
     (VP said
         (SBAR that
               (S (NP-SBJ the sale)
                  (VP will
                      (VP facilitate
                          (NP (NP (NP Gen-Probe 's)
				  marketing)
                              (PP of
                                  (NP (NP a diagnostic test)
                                      (PP for
                                          (NP (NP acquired immune deficiency syndrome)
                                              , or
                                              (NP AIDS)))))))))))
     .))
( (S (S-TPC-1 (NP-SBJ Chugai)
	      (ADVP also)
	      (VP will
		  (VP help
		      (NP Gen-Probe)
		      (PP-MNR with
			      (NP (NP its
				      (ADJP regulatory and marketing)
				      expertise)
				  (PP-LOC in
					  (NP Asia)))))))
     ,
     (NP-SBJ Mr. Bologna)
     (VP said
	  (SBAR 0
		(S *T*-1)))
     .))
( (S (S-TPC-2 (NP-SBJ-1 (NP The tender offer)
			(PP for
			    (NP (NP Gen-Probe 's)
				shares)))
	      (VP is
		  (VP expected
		      (S (NP-SBJ *-1)
			 (VP to
			     (VP begin
				 (NP-TMP-CLR next Monday)))))))
     ,
     (NP-SBJ the company)
     (VP said
	  (SBAR 0
		(S *T*-2)))
     .))
